Genta incorporated – product pipeline review – 2012


Published on

2012 | Genta Incorporated – Product Pipeline Review – 2012

  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Genta incorporated – product pipeline review – 2012

  1. 1. announces, The Latest market research report is available inits vast collection:Genta Incorporated – Product Pipeline Review – 2012You can also request for sample page of above mention reports onsample@aarkstore.comSummaryGlobal Markets Direct’s pharmaceuticals report, “Genta Incorporated - ProductPipeline Review - 2012” provides data on the Genta Incorporated’s research anddevelopment focus. The report includes information on current developmentalpipeline, complete with latest updates, and features on discontinued and dormantprojects.This report is built using data and information sourced from Global Markets Direct’sproprietary databases, Genta Incorporated’s corporate website, SEC filings, investorpresentations and featured press releases, both from Genta Incorporated andindustry-specific third party sources, put together by Global Markets Direct’s team.Scope- Genta Incorporated - Brief Genta Incorporated overview including businessdescription, key information and facts, and its locations and subsidiaries.- Review of current pipeline of Genta Incorporated human therapeutic division.- Overview of pipeline therapeutics across various therapy areas.Table of contents:List of Tables 5
  2. 2. List of Figures 5Genta Incorporated Snapshot 6Genta Incorporated Overview 6Key Information 6Key Facts 6Genta Incorporated – Research and Development Overview 7Key Therapeutic Areas 7Genta Incorporated – Pipeline Review 9Pipeline Products by Stage of Development 9Pipeline Products – Monotherapy 10Pipeline Products – Combination Treatment Modalities 11Genta Incorporated – Pipeline Products Glance 12Genta Incorporated Clinical Stage Pipeline Products 12Phase II Products/Combination Treatment Modalities 12Phase I Products/Combination Treatment Modalities 13Genta Incorporated – Drug Profiles 14G4544 14Product Description 14Mechanism of Action 14R&D Progress 14Ganite 16Product Description 16Mechanism of Action 16R&D Progress 16Tesetaxel 17Product Description 17Mechanism of Action 17R&D Progress 17Tesetaxel + Capecitabine 19Product Description 19Mechanism of Action 19R&D Progress 19Tesetaxel + Cisplatin + Capecitabine 21Product Description 21Mechanism of Action 21
  3. 3. R&D Progress 21List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Product Pipeline Review – 2012 PipelineReview – 2012&PubId=&pagenum=1Genta Incorporated – Product Pipeline Review – 2012Geron Corporation – Product Pipeline Review – 2012Glenmark Pharmaceuticals Ltd. – Product Pipeline Review – 2012iBio, Inc. – Product Pipeline Review – 2012ImmunoGen, Inc. – Product Pipeline Review – 2012Can-Fite BioPharma Ltd. – Product Pipeline Review – 2012Celtic Biotech, Ltd. – Product Pipeline Review – 2012Cyclacel Pharmaceuticals Inc. – Product Pipeline Review – 2012Endocyte, Inc. – Product Pipeline Review – 2012
  4. 4. Flamel Technologies S.A. – Product Pipeline Review – 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcare andHealthcare&PubId=&pagenum=1For More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585Email: